Reviving the Ross Operation

The adult congenital heart unit at the Freeman hospital has joined a multi-centre study, the REVIVAL study, designed to compare the Ross procedure with other surgical options for aortic valve replacement. 

Heart valves help control blood flow through the heart and, if diseased, may need to be replaced. There are different methods for doing this, each with their own advantages and disadvantages. In young adults, replacing the aortic heart valve with a mechanical valve can reduce life expectancy. Mechanical valves tend to form blood clots so they need long-term blood thinners which themselves can cause bleeding and lower quality of life. Animal tissue valves reduce clotting and bleeding risks but wear out sooner and shorten patient life-span. An operation, called the Ross procedure, replaces a patient’s diseased aortic valve with his/her own pulmonary valve and uses a donor valve in the pulmonary position which receives less stress than the aortic valve. The Ross procedure aims to improve valve durability with less clotting whilst avoiding use of blood thinners. REVIVAL is a research study investigating the efficacy and safety of the Ross procedure compared to conventional valve replacement. Specifically we are interested in learning the number of patients who survive without a life-threatening valve related complication, long term postoperatively.

For more information contact: mohamed.nassar2@nhs.net

Aortic arch grant success

Abnormalities of the heart are the most common birth defect and can affect the aortic arch arteries (the large blood vessels that carry blood away from the heart and deliver it to the whole body). Simon Bamforth and Helen Phillips in collaboration with Prof Nicoletta Bobola at the University of Manchester, have been awarded a 3-year project grant from the British Heart Foundation to study the genetic control of arch artery development. Combining the study of anatomy with state-of-the-art single cell transcriptomics they hope to unravel the complex networks of genes that are required to be expressed at the right time and in the correct place to ensure that our heart and blood vessels will develop properly and effectively deliver oxygenated blood around the body.

For more information, contact: simon.bamforth@newcastle.ac.uk

Mitral valve development

From Bill Chaudhry and Deb Henderrson

Mr Francis Wells, the internationally recognised cardiac surgeon from Papworth Hospital Cambridge, and our longstanding colleague Professor Bob Anderson, are in the late stages of producing a book for Springer Nature Publishers about the degenerating mitral valve. The work is aimed at clinicians and provides a broad discussion of the mitral valve from a scientific perspective. It is especially timely as the  developmental basis of many degenerative conditions, for example mitral valve prolapse, are increasingly recognised. We are honoured to be involved and have written a chapter explaining the developmental molecular genetics that control mitral valve development. Our chapter is specifically written for the clinician, outlining important aspects, but not burdening with scientific jargon. It is of relevance to topics of our research including hypoplastic left heart syndrome, atrioventricular septal defects and bicuspid aortic valve. Developmental anatomy and surgical aspects are provided by Bob and Francis in other chapters, and a host of international experts are adding their expertise in clinical genetics and physiology. We will post publication details in due course.

What do patients with ACHD really think?

The physical and emotional long-term effects of having CHD are usually seen from the medical viewpoint. But increasingly we are aware that the clinic is not always aligned to what patients might actually want or feel. The ACHD team in Newcastle have joined the Approach IS II study lead by Philip Moons in Belgium. This international study will explore how patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs), differ between patients in different countries and also try to identify the healthcare needs of older adults with congenital heart disease, who may be quite frail. 

To find out more contact louise.coats@newcastle.ac.uk

Hello, Hello – Its Good to be Back!

from Newcastle University Congenital Heart Disease Group

The Faculty of Medical Sciences at Newcastle University was completely reorganised in 2019. We reduced our number of institutes from six to three: the BiosciencesTranslational and Clinical Research and Population Health Sciences Institutes.

As part of this restructuring the old research centres, including the Cardiovascular Research Centre, were dissolved. In their place are Themes that cut across all three Institutes and are focussed on the future direction of academic research in our University. 

We, congenital heart researchers, have taken the opportunity to make new connections with others in the Reproduction, Development and Child Health (RDCH) Theme. We remain closely linked, but distinct from our colleagues in the Vascular Biology and Medicine (VBM) Theme and some colleagues have joint affiliation. Congenital heart clinicians in Newcastle hospitals, who are active in research, are affiliated to the Congenital Heart Disease research group and the RDCH Theme. We are also part of a wider community through the North East and North Cumbria Congenital Heart Disease Network.

On these web pages, we will post information about our research, our meetings and list contact details about our members. Enquiries about congenital heart disease research should be directed to louise.coats@ncl.ac.uk or bill.chaudhry@ncl.ac.uk and we will try to connect you with the right people.